α-硫辛酸联合还原型谷胱甘肽治疗乙型肝炎肝硬化的临床观察

目的:观察α-硫辛酸联合还原型谷胱甘肽治疗乙型肝炎肝硬化的临床效果。方法:将75例乙型肝炎肝硬化患者随机分为治疗组(40例)与对照组(35例)。2组均予以常规综合护肝治疗,治疗组给予α-硫辛酸0.45g+还原型谷胱甘肽1.2g,静脉滴注;对照组仅给予还原型谷胱甘肽1.2 g静脉滴注。2组疗程均为6周。观察2组治疗前后的肝功能指标(丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)和直接胆红素(DBIL),肝纤维化指标(玻璃酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)和Ⅳ型胶原(ⅣC))。结果:2组患者治疗后的ALT、AST、TBIL、DBIL、HA、LN、PCⅢ和ⅣC水平均低于治疗前,且治疗组同期水平低于对照组,差异均有统计学意义(P<0.05)。2组均未见严重不良反应发生。结论:α-硫辛酸联合还原型谷胱甘肽治疗乙型肝炎肝硬化疗效、安全性较好。

Clinical Observation of a-lipoic Acid Combined with Reduced Glutathione for Liver Cirrhosis Induced by Hepatitis B

OBJECTIVE： To observe the clinical efficacy of α-lipoic acid （a-LA） combined with reduced glutathione in the treatment of liver cirrhosis induced by hepatitis B. METHODS： 75 liver cirrhosis induced by hepatitis B were randomly divided into treatment group （n=40） and control group （n=35）. 2 groups were given conventional treatment of liver protection. Treatment group received a-lipoic acid 0.45 g＋intravenous dripping of reduced glutathione 1.2 g, and control group received intravenous dripping of reduced glutathione 1.2 g for 6 weeks. Liver function indexes were observed before and after treatment, such as ALT, AST, TBIL, DBIL. Liver fibrosis indexes were hyaluronic acid （HA）, laminin （LN）, procollagen type Ⅲ （PC Ⅲ ） and type Ⅳ collagen （Ⅳ C）. RESULTS, The levels ofALT, AST, TBIL, DBIL, HA, LN, PC Ⅲ and Ⅳ C in 2 groups were improved after treatment, those indexes of treatment group were lower than those of control group, there was significant difference （P〈0.05）. No adverse drug reaction was found in 2 groups. CONCLUSION： α-lipoic acid combined with reduced glutathione is effective and safe in the treatment of liver cirrhosis induced by hepatitis B.